The drug name behind Mounjaro — and what it tells you

You've seen the word tirzepatide, here's where it comes from

Picture this: you've been handed a prescription that says "Mounjaro 5mg solution for injection" and you want to look it up yourself before your first pen arrives. The word to search is tirzepatide, that's the international non-proprietary name (INN) assigned by the World Health Organization, and it stays constant across every country where the medicine is sold.

Mounjaro is Eli Lilly's chosen brand name in the UK and most of Europe, and if you're curious about where the Mounjaro name itself comes from, that page goes into the detail behind it. Brand names are commercial; drug names are scientific. The same active molecule might, in theory, reach the market under a different brand name elsewhere, but the INN remains the same. You can see this clearly on the tirzepatide entry in the BNF, which lists it under the drug name and notes Mounjaro as the current UK brand. One quick check of that page and you know exactly what you're looking at.

The practical value is real. When a prescriber writes your prescription, when the pharmacy labels your pen, and when you report a side effect to the MHRA, tirzepatide is the word that travels cleanly across all those contexts. Brand names change; the INN does not.

A dual mechanism, and why it sets tirzepatide apart from its nearest neighbours

Tirzepatide's drug name hints at nothing about its mechanism, but the mechanism is worth understanding, because it's the thing that makes it clinically distinct. Most GLP-1 medicines (semaglutide being the best-known example) activate a single receptor pathway. Tirzepatide activates two: the GIP receptor and the GLP-1 receptor.

Both pathways are involved in appetite regulation and blood-sugar control. When both are engaged together, the appetite-suppressing and glucose-lowering signals appear stronger than either alone. In the SURMOUNT-1 trial, participants taking the highest dose of tirzepatide lost around 20–21% of their body weight on average over 72 weeks, results published in the New England Journal of Medicine that helped inform NICE's decision to recommend tirzepatide on the NHS in December 2024. In a subsequent head-to-head study (SURMOUNT-5) tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks.

None of that tells you whether tirzepatide is right for you, that is a clinical decision shaped by your health history, other medicines you take, and your BMI. But knowing the mechanism helps you ask better questions. You can read more about tirzepatide as a treatment in detail, or look at the full Mounjaro overview if you want to understand how the drug is used in practice.

Drug name vs brand name: what it means for checking your medicine

When your pen arrives, the label will say Mounjaro. The leaflet inside will say tirzepatide. The summary of characteristics filed with the MHRA uses both. Understanding this avoids a common moment of uncertainty, people occasionally contact pharmacies worried that the pen and the leaflet are for different medicines. They're not.

There's a practical checking habit worth building into your first delivery: before injecting, match the dose printed on the pen (for example, 5 mg/0.5 ml) against the dose on your prescription. The NHS medicines page for tirzepatide lists the UK dose strengths (2.5, 5, 7.5, 10, 12.5, and 15 mg) so you can confirm at a glance that what you're holding is what was prescribed. That takes about thirty seconds and removes any doubt.

If you're looking at the broader landscape of how tirzepatide appears under different names across markets, that page has the detail. And if you've come across "Zepbound", that is the US brand name for the same drug; it is not a UK product and is not available from UK pharmacies.

How the drug name affects your NHS and private access options

NICE recommended tirzepatide (under the drug name, in guidance reference TA1026) for NHS use in December 2024, with NHS England phasing access by BMI and the number of qualifying health conditions. The NHS prescription will always show the brand name Mounjaro alongside the INN tirzepatide, both appear because UK prescribing conventions allow either to trigger a dispense of the same product.

For people accessing tirzepatide privately (which remains the route for anyone who doesn't meet the current NHS criteria or doesn't want to wait) the process starts with a clinical consultation rather than a GP referral. If you want to understand what that involves, the Mounjaro for weight loss page covers eligibility and what to expect. Cost is a fair question too; a factual breakdown of the UK private market is available on the Mounjaro price comparison page.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber, a named clinician, not automated screening. Tirzepatide is a prescription-only medicine, and that clinical review is not a formality; it's the safeguard that makes the treatment appropriate. If you'd like to check your eligibility, the consultation is free and reviewed the same day.